Literature DB >> 19037056

ACOG Committee Opinion No. 422: at-risk drinking and illicit drug use: ethical issues in obstetric and gynecologic practice.

.   

Abstract

Drug and alcohol abuse is a major health problem for American women regardless of their socioeconomic status, race, ethnicity, and age. It is costly to individuals and to society. Obstetrician-gynecologists have an ethical obligation to learn and use a protocol for universal screening questions, brief intervention, and referral to treatment in order to provide patients and their families with medical care that is state-of-the-art, comprehensive, and effective. In this Committee Opinion, the American College of Obstetricians and Gynecologists' Committee on Ethics proposes an ethical rationale for this protocol in both obstetric and gynecologic practice, offers a practical aid for incorporating such care, and provides guidelines for resolving common ethical dilemmas related to drug and alcohol use that arise in the clinical setting.

Entities:  

Mesh:

Year:  2008        PMID: 19037056     DOI: 10.1097/AOG.0b013e318192499b

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  25 in total

1.  Women's perspectives on screening for alcohol and drug use in prenatal care.

Authors:  Sarah C M Roberts; Amani Nuru-Jeter
Journal:  Womens Health Issues       Date:  2010 May-Jun

2.  Pharmacotherapy and pregnancy: highlights from the Second International Conference for Individualized Pharmacotherapy in Pregnancy.

Authors:  David M Haas; Mary F Hebert; Offie P Soldin; David A Flockhart; Parvaz Madadi; James J Nocon; Christina D Chambers; Gary D Hankins; Shannon Clark; Katherine L Wisner; Lang Li; Jamie L Renbarger; Lee A Learman
Journal:  Clin Transl Sci       Date:  2009-12       Impact factor: 4.689

3.  Detection of alcohol use in the second trimester among low-income pregnant women in the prenatal care settings in Jefferson County, Alabama.

Authors:  Qing Li; Janet Hankin; Sharon C Wilsnack; Ernest L Abel; Russell S Kirby; Louis G Keith; Sarah G Obican
Journal:  Alcohol Clin Exp Res       Date:  2012-02-29       Impact factor: 3.455

Review 4.  Illicit substance use in pregnancy - a review.

Authors:  Katherine Scott; Karin Lust
Journal:  Obstet Med       Date:  2010-09-17

5.  Neurobehavioral Disorder Associated With Prenatal Alcohol Exposure.

Authors:  Joseph F Hagan; Tatiana Balachova; Jacquelyn Bertrand; Ira Chasnoff; Elizabeth Dang; Daniel Fernandez-Baca; Julie Kable; Barry Kosofsky; Yasmin N Senturias; Natasha Singh; Mark Sloane; Carol Weitzman; Jennifer Zubler
Journal:  Pediatrics       Date:  2016-10       Impact factor: 7.124

6.  Refining Measurement of Substance Use Disorders Among Women of Child-Bearing Age Using Hospital Records: The Development of the Explicit-Mention Substance Abuse Need for Treatment in Women (EMSANT-W) Algorithm.

Authors:  Taletha Mae Derrington; Judith Bernstein; Candice Belanoff; Howard J Cabral; Hermik Babakhanlou-Chase; Hafsatou Diop; Stephen R Evans; Milton Kotelchuck
Journal:  Matern Child Health J       Date:  2015-10

7.  The feasibility and cost of neonatal screening for prenatal alcohol exposure by measuring phosphatidylethanol in dried blood spots.

Authors:  Ludmila N Bakhireva; Renate D Savich; Dennis W Raisch; Sandra Cano; Robert D Annett; Lawrence Leeman; Mahek Garg; Chelsea Goff; Daniel D Savage
Journal:  Alcohol Clin Exp Res       Date:  2013-02-19       Impact factor: 3.455

8.  Complex calculations: how drug use during pregnancy becomes a barrier to prenatal care.

Authors:  Sarah C M Roberts; Cheri Pies
Journal:  Matern Child Health J       Date:  2011-04

9.  Performance measurement: a proposal to increase use of SBIRT and decrease alcohol consumption during pregnancy.

Authors:  Peggy L O'Brien
Journal:  Matern Child Health J       Date:  2014-01

10.  Illicit drug use among pregnant women enrolled in treatment for cigarette smoking cessation.

Authors:  Diann E Gaalema; Stephen T Higgins; Christopher S Pepin; Sarah H Heil; Ira M Bernstein
Journal:  Nicotine Tob Res       Date:  2012-10-15       Impact factor: 4.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.